Skip to main content
Top
Published in: Malaria Journal 1/2017

Open Access 01-12-2017 | Research

Screening a protein kinase inhibitor library against Plasmodium falciparum

Authors: Irene Hallyburton, Raffaella Grimaldi, Andrew Woodland, Beatriz Baragaña, Torsten Luksch, Daniel Spinks, Daniel James, Didier Leroy, David Waterson, Alan H. Fairlamb, Paul G. Wyatt, Ian H. Gilbert, Julie A. Frearson

Published in: Malaria Journal | Issue 1/2017

Login to get access

Abstract

Background

Protein kinases have been shown to be key drug targets, especially in the area of oncology. It is of interest to explore the possibilities of protein kinases as a potential target class in Plasmodium spp., the causative agents of malaria. However, protein kinase biology in malaria is still being investigated. Therefore, rather than assaying against individual protein kinases, a library of 4731 compounds with protein kinase inhibitor-like scaffolds was screened against the causative parasite, Plasmodium falciparum. This approach is more holistic and considers the whole kinome, making it possible to identify compounds that inhibit more than one P. falciparum protein kinase, or indeed other malaria targets.

Results

As a result of this screen, 9 active compound series were identified; further validation was carried out on 4 of these series, with 3 being progressed into hits to lead chemistry. The detailed evaluation of one of these series is described.

Discussion

This screening approach proved to be an effective way to identify series for further optimisation against malaria. Compound optimisation was carried out in the absence of knowledge of the molecular target. Some of the series had to be halted for various reasons. Mode of action studies to find the molecular target may be useful when problems prevent further chemical optimisation.

Conclusions

Progressible series were identified through phenotypic screening of a relatively small focused kinase scaffold chemical library.
Appendix
Available only for authorised users
Literature
1.
go back to reference Fairlamb AH, Gow NAR, Matthews KR, Waters AP. Drug resistance in eukaryotic microorganisms. Nat Microbiol. 2016;1:e16092.CrossRef Fairlamb AH, Gow NAR, Matthews KR, Waters AP. Drug resistance in eukaryotic microorganisms. Nat Microbiol. 2016;1:e16092.CrossRef
2.
go back to reference Blasco B, Leroy D, Fidock DA. Antimalarial drug resistance: linking Plasmodium falciparum parasite biology to the clinic. Nat Med. 2017;23:917–28.CrossRefPubMed Blasco B, Leroy D, Fidock DA. Antimalarial drug resistance: linking Plasmodium falciparum parasite biology to the clinic. Nat Med. 2017;23:917–28.CrossRefPubMed
3.
go back to reference Jirage D, Keenan SM, Waters NC. Exploring novel targets for antimalarial drug discovery: plasmodial protein kinases. Infect Disord Drug Targets. 2010;10:134–46.CrossRefPubMed Jirage D, Keenan SM, Waters NC. Exploring novel targets for antimalarial drug discovery: plasmodial protein kinases. Infect Disord Drug Targets. 2010;10:134–46.CrossRefPubMed
5.
go back to reference Anamika, Srinivasan N, Krupa A. A genomic perspective of protein kinases in Plasmodium falciparum. Proteins. 2005;58:180–9.CrossRefPubMed Anamika, Srinivasan N, Krupa A. A genomic perspective of protein kinases in Plasmodium falciparum. Proteins. 2005;58:180–9.CrossRefPubMed
6.
go back to reference Ward P, Equinet L, Packer J, Doerig C. Protein kinases of the human malaria parasite Plasmodium falciparum: the kinome of a divergent eukaryote. BMC Genomics. 2004;5:79.CrossRefPubMedPubMedCentral Ward P, Equinet L, Packer J, Doerig C. Protein kinases of the human malaria parasite Plasmodium falciparum: the kinome of a divergent eukaryote. BMC Genomics. 2004;5:79.CrossRefPubMedPubMedCentral
7.
go back to reference Lucet IS, Tobin A, Drewry D, Wilks AF, Doerig C. Plasmodium kinases as targets for new-generation antimalarials. Future Med Chem. 2012;4:2295–310.CrossRefPubMed Lucet IS, Tobin A, Drewry D, Wilks AF, Doerig C. Plasmodium kinases as targets for new-generation antimalarials. Future Med Chem. 2012;4:2295–310.CrossRefPubMed
8.
go back to reference Doerig C. Protein kinases as targets for anti-parasitic chemotherapy. BBA-Proteins Proteomics. 2004;1697:155–68.CrossRefPubMed Doerig C. Protein kinases as targets for anti-parasitic chemotherapy. BBA-Proteins Proteomics. 2004;1697:155–68.CrossRefPubMed
10.
go back to reference Paquet T, Le Manach C, Cabrera DG, Younis Y, Henrich PP, Abraham TS, et al. Antimalarial efficacy of MMV390048, an inhibitor of Plasmodium phosphatidylinositol 4-kinase. Sci Transl Med. 2017;9:eaad9735.CrossRefPubMed Paquet T, Le Manach C, Cabrera DG, Younis Y, Henrich PP, Abraham TS, et al. Antimalarial efficacy of MMV390048, an inhibitor of Plasmodium phosphatidylinositol 4-kinase. Sci Transl Med. 2017;9:eaad9735.CrossRefPubMed
11.
go back to reference Solyakov L, Halbert J, Alam MM, Semblat JP, Dorin-Semblat D, Reininger L, et al. Global kinomic and phospho-proteomic analyses of the human malaria parasite Plasmodium falciparum. Nat Commun. 2011;2:565.CrossRefPubMed Solyakov L, Halbert J, Alam MM, Semblat JP, Dorin-Semblat D, Reininger L, et al. Global kinomic and phospho-proteomic analyses of the human malaria parasite Plasmodium falciparum. Nat Commun. 2011;2:565.CrossRefPubMed
12.
go back to reference Brenk R, Schipani A, James D, Krasowski A, Gilbert IH, Frearson J, et al. Lessons learnt from assembling screening libraries for drug discovery for neglected diseases. Chem Med Chem. 2008;3:435–44.CrossRefPubMed Brenk R, Schipani A, James D, Krasowski A, Gilbert IH, Frearson J, et al. Lessons learnt from assembling screening libraries for drug discovery for neglected diseases. Chem Med Chem. 2008;3:435–44.CrossRefPubMed
14.
go back to reference Bennett TN, Paguio M, Gligorijevic B, Seudieu C, Kosar AD, Davidson E, et al. Novel, rapid, and inexpensive cell-based quantification of antimalarial drug efficacy. Antimicrob Agents Chemother. 2004;48:1807–10.CrossRefPubMedPubMedCentral Bennett TN, Paguio M, Gligorijevic B, Seudieu C, Kosar AD, Davidson E, et al. Novel, rapid, and inexpensive cell-based quantification of antimalarial drug efficacy. Antimicrob Agents Chemother. 2004;48:1807–10.CrossRefPubMedPubMedCentral
15.
go back to reference Jacobs JP, Jones CM, Baille JP. Characteristics of a human diploid cell designated MRC-5. Nature. 1970;227:168–70.CrossRefPubMed Jacobs JP, Jones CM, Baille JP. Characteristics of a human diploid cell designated MRC-5. Nature. 1970;227:168–70.CrossRefPubMed
16.
go back to reference Plouffe D, Brinker A, McNamara C, Henson K, Kato N, Kuhen K, et al. In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen. Proc Natl Acad Sci USA. 2008;105:9059–64.CrossRefPubMedPubMedCentral Plouffe D, Brinker A, McNamara C, Henson K, Kato N, Kuhen K, et al. In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen. Proc Natl Acad Sci USA. 2008;105:9059–64.CrossRefPubMedPubMedCentral
17.
go back to reference Chulay JD, Haynes JD, Diggs CL. Plasmodium falciparum: assessment of in vitro growth by [3H]hypoxanthine incorporation. Exp Parasitol. 1983;55:138–46.CrossRefPubMed Chulay JD, Haynes JD, Diggs CL. Plasmodium falciparum: assessment of in vitro growth by [3H]hypoxanthine incorporation. Exp Parasitol. 1983;55:138–46.CrossRefPubMed
18.
go back to reference Smith VC, Cleghorn LA, Woodland A, Spinks D, Hallyburton I, Collie IT, et al. Optimisation of the anti-Trypanosoma brucei activity of the opioid agonist U50488. Chem Med Chem. 2011;6:1832–40.CrossRefPubMedPubMedCentral Smith VC, Cleghorn LA, Woodland A, Spinks D, Hallyburton I, Collie IT, et al. Optimisation of the anti-Trypanosoma brucei activity of the opioid agonist U50488. Chem Med Chem. 2011;6:1832–40.CrossRefPubMedPubMedCentral
21.
go back to reference Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science. 2002;298:1912–34.CrossRefPubMed Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science. 2002;298:1912–34.CrossRefPubMed
22.
go back to reference Delves M, Plouffe D, Scheurer C, Meister S, Wittlin S, Winzeler E, Sinden RE, Leroy D. The activities of current antimalarial drugs on the life cycle stages of Plasmodium: a comparative study with human and rodent parasites. PLoS Med. 2012;9:e1001169.CrossRefPubMedPubMedCentral Delves M, Plouffe D, Scheurer C, Meister S, Wittlin S, Winzeler E, Sinden RE, Leroy D. The activities of current antimalarial drugs on the life cycle stages of Plasmodium: a comparative study with human and rodent parasites. PLoS Med. 2012;9:e1001169.CrossRefPubMedPubMedCentral
23.
go back to reference Norcross NR, Baragana B, Wilson C, Hallyburton I, Osuna-Cabello M, Norval S, et al. Trisubstituted pyrimidines as efficacious and fast-acting antimalarials. J Med Chem. 2016;59:6101–20.CrossRefPubMedPubMedCentral Norcross NR, Baragana B, Wilson C, Hallyburton I, Osuna-Cabello M, Norval S, et al. Trisubstituted pyrimidines as efficacious and fast-acting antimalarials. J Med Chem. 2016;59:6101–20.CrossRefPubMedPubMedCentral
24.
go back to reference Baragana B, Hallyburton I, Lee MC, Norcross NR, Grimaldi R, Otto TD, et al. A novel multiple-stage antimalarial agent that inhibits protein synthesis. Nature. 2015;522:315–20.CrossRefPubMedPubMedCentral Baragana B, Hallyburton I, Lee MC, Norcross NR, Grimaldi R, Otto TD, et al. A novel multiple-stage antimalarial agent that inhibits protein synthesis. Nature. 2015;522:315–20.CrossRefPubMedPubMedCentral
25.
go back to reference Baragana B, Norcross NR, Wilson C, Porzelle A, Hallyburton I, Grimaldi R, et al. Discovery of a quinoline-4-carboxamide derivative with a novel mechanism of action, multistage antimalarial activity, and potent in vivo efficacy. J Med Chem. 2016;59:9672–85.CrossRefPubMedPubMedCentral Baragana B, Norcross NR, Wilson C, Porzelle A, Hallyburton I, Grimaldi R, et al. Discovery of a quinoline-4-carboxamide derivative with a novel mechanism of action, multistage antimalarial activity, and potent in vivo efficacy. J Med Chem. 2016;59:9672–85.CrossRefPubMedPubMedCentral
27.
go back to reference Zhao H, Caflisch A. Current kinase inhibitors cover a tiny fraction of fragment space. Bioorg Med Chem Lett. 2015;25:2372–6.CrossRefPubMed Zhao H, Caflisch A. Current kinase inhibitors cover a tiny fraction of fragment space. Bioorg Med Chem Lett. 2015;25:2372–6.CrossRefPubMed
28.
go back to reference Leeson PD, Springthorpe B. The influence of drug-like concepts on decision-making in medicinal chemistry. Nat Rev Drug Discov. 2007;6:881–90.CrossRefPubMed Leeson PD, Springthorpe B. The influence of drug-like concepts on decision-making in medicinal chemistry. Nat Rev Drug Discov. 2007;6:881–90.CrossRefPubMed
29.
go back to reference Young RJ, Green DV, Luscombe CN, Hill AP. Getting physical in drug discovery II: the impact of chromatographic hydrophobicity measurements and aromaticity. Drug Discov Today. 2011;16:822–30.CrossRefPubMed Young RJ, Green DV, Luscombe CN, Hill AP. Getting physical in drug discovery II: the impact of chromatographic hydrophobicity measurements and aromaticity. Drug Discov Today. 2011;16:822–30.CrossRefPubMed
30.
go back to reference Ritchie TJ, MacDonald SJF. The impact of aromatic ring count on compound developability—are too many aromatic rings a liability in drug design? Drug Discov Today. 2009;14:1011–20.CrossRefPubMed Ritchie TJ, MacDonald SJF. The impact of aromatic ring count on compound developability—are too many aromatic rings a liability in drug design? Drug Discov Today. 2009;14:1011–20.CrossRefPubMed
31.
go back to reference Ritchie TJ, MacDonald SJF, Young RJ, Pickett SD. The impact of aromatic ring count on compound developability: further insights by examiing carbo- and hetero-aromatic and -aliphatic ring types. Drug Discov Today. 2011;16:164–71.CrossRefPubMed Ritchie TJ, MacDonald SJF, Young RJ, Pickett SD. The impact of aromatic ring count on compound developability: further insights by examiing carbo- and hetero-aromatic and -aliphatic ring types. Drug Discov Today. 2011;16:164–71.CrossRefPubMed
Metadata
Title
Screening a protein kinase inhibitor library against Plasmodium falciparum
Authors
Irene Hallyburton
Raffaella Grimaldi
Andrew Woodland
Beatriz Baragaña
Torsten Luksch
Daniel Spinks
Daniel James
Didier Leroy
David Waterson
Alan H. Fairlamb
Paul G. Wyatt
Ian H. Gilbert
Julie A. Frearson
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Malaria Journal / Issue 1/2017
Electronic ISSN: 1475-2875
DOI
https://doi.org/10.1186/s12936-017-2085-4

Other articles of this Issue 1/2017

Malaria Journal 1/2017 Go to the issue